Skip to main content

26 April 2024

Last updated: Thursday 25 April 2024

User account anon menu

Login
Register and subscribe

Search

Home
News
About MedNous
Research Directory
Contact Us
- Contact Form

Menu

Breadcrumb

Home
Why Oxford BioTherapeutics Is Targeting ADCs

Why Oxford BioTherapeutics is targeting ADCs

Sunday 13 November 2011

Interviewee/Contributor

Christian Rohlff

Organisation

Oxford BioTherapeutics Ltd

---Subscribe to MedNous to access this article---

Antibody Drug Conjugates ADCs

Select a News Category

Clinical Research
Company News
Finance, Grants, Deals
IPR & Legal
Regenerative Medicine
Regulation & Policy
Research & University News

Recent Appointments

4BIO Capital adds to advisory board

Saturday 30 March 2024

Metrion names CFO, two new hires

Saturday 30 March 2024

CDMO expert joins Oxford Biomedica board

Saturday 30 March 2024

Neurodegenerative disease experts join Asceneuron science board

Saturday 30 March 2024

Lundbeck makes changes to executive management

Saturday 30 March 2024

View more appointments

Looking for more?

MedNous covers medical news and more. See more in our various site sections.

News
Industry appointments
Events
Research directory
Subscribe

Footer

Privacy policy

© 2024 Evernow Publishing Ltd.

Home
News
- News
- Appointments
- Events
About MedNous
Research Directory
Contact Us
- Contact Form